Q3 EPS Estimate for Vertex Pharmaceuticals Raised by Analyst

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Equities research analysts at Zacks Research upped their Q3 2025 earnings estimates for shares of Vertex Pharmaceuticals in a research note issued on Tuesday, December 24th. Zacks Research analyst R. Department now expects that the pharmaceutical company will earn $4.01 per share for the quarter, up from their prior estimate of $3.99. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is ($1.83) per share.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.77. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The company had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.69 billion. During the same quarter in the prior year, the firm earned $3.67 earnings per share. The company’s revenue for the quarter was up 11.6% compared to the same quarter last year.

Several other analysts also recently issued reports on VRTX. Morgan Stanley upped their price objective on Vertex Pharmaceuticals from $473.00 to $476.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 5th. Needham & Company LLC restated a “hold” rating on shares of Vertex Pharmaceuticals in a report on Friday, December 20th. Raymond James reiterated a “market perform” rating on shares of Vertex Pharmaceuticals in a report on Thursday, October 10th. Royal Bank of Canada upped their price objective on shares of Vertex Pharmaceuticals from $437.00 to $451.00 and gave the company a “sector perform” rating in a research note on Tuesday, November 5th. Finally, Truist Financial lowered their target price on shares of Vertex Pharmaceuticals from $550.00 to $460.00 and set a “buy” rating for the company in a research note on Monday, December 23rd. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $494.04.

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ:VRTX opened at $408.76 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.20 and a current ratio of 2.47. The business’s fifty day moving average price is $462.47 and its two-hundred day moving average price is $472.74. The stock has a market cap of $105.27 billion, a PE ratio of -205.41 and a beta of 0.36. Vertex Pharmaceuticals has a one year low of $377.85 and a one year high of $519.88.

Institutional Investors Weigh In On Vertex Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of VRTX. Strategic Blueprint LLC boosted its holdings in Vertex Pharmaceuticals by 12.5% in the 2nd quarter. Strategic Blueprint LLC now owns 1,080 shares of the pharmaceutical company’s stock worth $506,000 after acquiring an additional 120 shares during the period. Whittier Trust Co. grew its holdings in Vertex Pharmaceuticals by 9.2% during the 2nd quarter. Whittier Trust Co. now owns 1,447 shares of the pharmaceutical company’s stock valued at $678,000 after purchasing an additional 122 shares in the last quarter. Ameritas Advisory Services LLC purchased a new stake in Vertex Pharmaceuticals during the 2nd quarter worth $591,000. Key Financial Inc lifted its holdings in Vertex Pharmaceuticals by 502.0% in the 2nd quarter. Key Financial Inc now owns 301 shares of the pharmaceutical company’s stock worth $141,000 after buying an additional 251 shares in the last quarter. Finally, International Assets Investment Management LLC purchased a new position in Vertex Pharmaceuticals in the 2nd quarter valued at about $205,000. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.